These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20375169)

  • 1. Persistence of viremia and production of neutralizing antibodies differentially regulated by polymorphic APOBEC3 and BAFF-R loci in friend virus-infected mice.
    Tsuji-Kawahara S; Chikaishi T; Takeda E; Kato M; Kinoshita S; Kajiwara E; Takamura S; Miyazawa M
    J Virol; 2010 Jun; 84(12):6082-95. PubMed ID: 20375169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo.
    Santiago ML; Benitez RL; Montano M; Hasenkrug KJ; Greene WC
    J Immunol; 2010 Jul; 185(2):1114-23. PubMed ID: 20566830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional B-cell-activating factor receptor.
    Santiago ML; Smith DS; Barrett BS; Montano M; Benitez RL; Pelanda R; Hasenkrug KJ; Greene WC
    J Virol; 2011 Jan; 85(1):189-99. PubMed ID: 20980520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection.
    Santiago ML; Montano M; Benitez R; Messer RJ; Yonemoto W; Chesebro B; Hasenkrug KJ; Greene WC
    Science; 2008 Sep; 321(5894):1343-6. PubMed ID: 18772436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo.
    Takeda E; Tsuji-Kawahara S; Sakamoto M; Langlois MA; Neuberger MS; Rada C; Miyazawa M
    J Virol; 2008 Nov; 82(22):10998-1008. PubMed ID: 18786991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type I interferon signaling is required for the APOBEC3/Rfv3-dependent neutralizing antibody response but not innate retrovirus restriction.
    Barrett BS; Harper MS; Jones ST; Guo K; Heilman KJ; Kedl RM; Hasenkrug KJ; Santiago ML
    Retrovirology; 2017 Apr; 14(1):25. PubMed ID: 28415995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin somatic hypermutation by APOBEC3/Rfv3 during retroviral infection.
    Halemano K; Guo K; Heilman KJ; Barrett BS; Smith DS; Hasenkrug KJ; Santiago ML
    Proc Natl Acad Sci U S A; 2014 May; 111(21):7759-64. PubMed ID: 24821801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3.
    Harper MS; Barrett BS; Smith DS; Li SX; Gibbert K; Dittmer U; Hasenkrug KJ; Santiago ML
    J Immunol; 2013 Feb; 190(4):1583-90. PubMed ID: 23315078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Requirement for CD4(+) T cells in the Friend murine retrovirus neutralizing antibody response: evidence for functional T cells in genetic low-recovery mice.
    Super HJ; Brooks D; Hasenkrug K; Chesebro B
    J Virol; 1998 Nov; 72(11):9400-3. PubMed ID: 9765497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Requirement for Fc effector mechanisms in the APOBEC3/Rfv3-dependent neutralizing antibody response.
    Halemano K; Barrett BS; Heilman KJ; Morrison TE; Santiago ML
    J Virol; 2015 Apr; 89(7):4011-4. PubMed ID: 25589647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response.
    Smith DS; Guo K; Barrett BS; Heilman KJ; Evans LH; Hasenkrug KJ; Greene WC; Santiago ML
    PLoS Pathog; 2011 Oct; 7(10):e1002284. PubMed ID: 21998583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fv1 restriction and retrovirus vaccine immunity in Apobec3-deficient 129P2 mice.
    Halemano K; Barrett BS; Li SX; Harper MS; Smith DS; Heilman KJ; Santiago ML
    PLoS One; 2013; 8(3):e60500. PubMed ID: 23533681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reassessment of murine APOBEC1 as a retrovirus restriction factor in vivo.
    Barrett BS; Guo K; Harper MS; Li SX; Heilman KJ; Davidson NO; Santiago ML
    Virology; 2014 Nov; 468-470():601-608. PubMed ID: 25303118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host genetic factors that control immune responses to retrovirus infections.
    Miyazawa M; Tsuji-Kawahara S; Kanari Y
    Vaccine; 2008 Jun; 26(24):2981-96. PubMed ID: 18255203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class switch recombination and somatic hypermutation of virus-neutralizing antibodies are not essential for control of friend retrovirus infection.
    Kato M; Tsuji-Kawahara S; Kawasaki Y; Kinoshita S; Chikaishi T; Takamura S; Fujisawa M; Kawada A; Miyazawa M
    J Virol; 2015 Jan; 89(2):1468-73. PubMed ID: 25378499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Filariae-Retrovirus Co-infection in Mice is Associated with Suppressed Virus-Specific IgG Immune Response and Higher Viral Loads.
    Dietze KK; Dittmer U; Koudaimi DK; Schimmer S; Reitz M; Breloer M; Hartmann W
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005170. PubMed ID: 27923052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection.
    Dittmer U; Peterson KE; Messer R; Stromnes IM; Race B; Hasenkrug KJ
    J Virol; 2001 Jan; 75(2):654-60. PubMed ID: 11134279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of type I interferons on Friend retrovirus infection.
    Gerlach N; Schimmer S; Weiss S; Kalinke U; Dittmer U
    J Virol; 2006 Apr; 80(7):3438-44. PubMed ID: 16537611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetherin/BST-2 promotes dendritic cell activation and function during acute retrovirus infection.
    Li SX; Barrett BS; Guo K; Kassiotis G; Hasenkrug KJ; Dittmer U; Gibbert K; Santiago ML
    Sci Rep; 2016 Feb; 6():20425. PubMed ID: 26846717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of friend retrovirus in the absence of CD8+ T cells.
    Tsuji-Kawahara S; Miyazawa M
    J Virol; 2014 Feb; 88(3):1854-5. PubMed ID: 24227860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.